Interferon-α as an Effective Treatment for Noninfectious Posterior Uveitis and Panuveitis

American Journal of Ophthalmology

Volumn 144, Issue 1, 2007, Pages

  Plskova, Jarka ^a   Greiner, Kathrin ^a   Forrester, John V ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RECOMBINANT ALPHA2B INTERFERON; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA RECEPTOR IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; AMNESIA; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY SKIN; DYSMENORRHEA; DYSPNEA; EPISTAXIS; EYE TOXICITY; FATIGUE; FEMALE; FIBROMYALGIA; FLU LIKE SYNDROME; HAIR LOSS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE ERYTHEMA; INJECTION SITE INFECTION; INTERVENTION STUDY; LYMPHOCYTOPENIA; MALE; MOUTH ULCER; NAUSEA AND VOMITING; ONYCHOMYCOSIS; OPHTHALMOSCOPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; PSORIASIS; RASH; RETINA MACULA EDEMA; RETINOPATHY; RETINOTOXICITY; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STINGY TONGUE; SUICIDE ATTEMPT; THYROID DISEASE; TREATMENT DURATION; TREATMENT FAILURE; UVEITIS; VISUAL ACUITY; WEIGHT REDUCTION; XEROSTOMIA;

EID: 34250778993     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2007.03.050     Document Type: Article

References (28)

1. Gordon D.M. Prednisone and prednisolone in ocular disease. Am J Ophthalmol 41 (1956) 593-600
2. Dick A.D., Azim M., and Forrester J.V. Immunosuppressive therapy for chronic uveitis: optimizing therapy with steroids and cyclosporin A. Br J Ophthalmol 81 (1997) 1107-1112
3. Greiner K., Murphy C.C., Willermain F., et al. Anti-TNF-alpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci 45 (2004) 170-176
4. Murphy C.C., Greiner K., Plskova J., et al. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol 122 (2004) 845-851
5. Palucka A.K., Blanck J.P., Bennett L., Pascual V., and Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 102 (2005) 3372-3377
6. Lindstedt E.W., Baarsma G.S., Kuijpers R.W., and van Hagen P.M. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 89 (2005) 5363-5366
7. Dick A.D., Forrester J.V., Liversidge J., and Cope A.P. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res 23 (2004) 617-637
8. Kotter I., Zierhut M., Eckstein A.K., et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87 (2003) 423-431
9. Sanchez Roman J., Pulido Aguilera M.C., Castillo Palma M.J., et al. [The use of interferon alfa-2r in the treatment of autoimmune uveitis (primary or associated with Behcet's disease)]. Rev Clin Esp 196 (1996) 293-298
10. Becker M.D., Heiligenhaus A., Hudde T., et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 89 (2005) 1254-1257
11. Pipitone N., Olivieri I., Cantini F., Triolo G., and Salvarani C. New approaches in the treatment of Adamantiades-Behcet's disease. Curr Opin Rheumatol 18 (2006) 3-9
12. Stoutenburg J.P., Schrope B., and Kaufman H.L. Adjuvant therapy for malignant melanoma. Expert Rev Anticancer Ther 4 (2004) 823-835
13. Saadeh S., and Davis G.L. The evolving treatment of chronic hepatitis C: where we stand a decade out. Cleve Clin J Med 71 (2004) S3-S7
14. Okada H., and Pollack I.F. Cytokine gene therapy for malignant glioma. Expert Opin Biol Ther 4 (2004) 1609-1620
15. Green A.R., Vassiliou G.S., Curtin N., and Campbell P.J. Management of the myeloproliferative disorders: distinguishing data from dogma. Hematol J 5 (2004) S126-S132
16. Jabs D.A., Nussenblatt R.B., Rosenbaum J.T., and Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140 (2005) 509-516
17. Windemuth D., Bacharach-Buhles M., Hoffmann K., and Altmeyer P. [Depression and suicidal intentions as a side effect of high dosage interferon-alpha therapy-two cases]. Hautarzt 50 (1999) 266-269
18. Rifflet H., Vuillemin E., Oberti F., et al. [Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon-alpha]. Gastroenterol Clin Biol 22 (1998) 353-357
19. Russo D., Zuffa E., Bandini G., Baccarani M., and Tura S. Mental depression, acute infection and coma in a patient treated with interferon-alpha. Haematologica 74 (1989) 228
20. Scalori A., Pozzi M., Bellia V., et al. Interferon-induced depression: prevalence and management. Dig Liver Dis 37 (2005) 102-107
21. Reichenberg A., Gorman J.M., and Dieterich D.T. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week Prospective Study. AIDS 19 (2005) S174-S178
22. Nickel T., Sonntag A., Backmund M., and Pollmacher T. Depression during therapy with interferon-alpha-how long should an anti-depressant treatment last?. Pharmacopsychiatry 38 (2005) 102-104
23. Hayasaka S., Fujii M., Yamamoto Y., Noda S., Kurome H., and Sasaki M. Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol 79 (1995) 150-152
24. Tu K.L., Bowyer J., Schofield K., and Harding S. Severe interferon associated retinopathy. Br J Ophthalmol 87 (2003) 247-248
25. Hayasaka S., Nagaki Y., Matsumoto M., and Sato S. Interferon associated retinopathy. Br J Ophthalmol 82 (1998) 323-325
26. Jain K., Lam W.C., Waheeb S., Thai Q., and Heathcote J. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol 85 (2001) 1171-1173
27. Cuthbertson F.M., Davies M., and McKibbin M. Is screening for interferon retinopathy in hepatitis C justified?. Br J Ophthalmol 88 (2004) 1518-1520
28. Oishi A., Miyamoto K., Kashii S., and Yoshimura N. Retinopathy is not the only ocular symptom: myasthenia gravis in association with interferon therapy. Br J Ophthalmol 89 (2005) 1542-1543